Treatment for chemotherapy-induced alopecia in mice using parathyroid hormone agonists and antagonists linked to a collagen binding domain

International Journal of Cancer

Volumn 131, Issue 5, 2012, Pages

  Katikaneni, Ranjitha ^a   Ponnapakkam, Tulasi ^a   Suda, Hirofumi ^b   Miyata, Shigeru ^c   Sakon, Joshua ^d   Matsushita, Osamu ^e   Gensure, Robert C ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b KAGAWA UNIVERSITY   (Japan)

^c CHUBU UNIVERSITY   (Japan)

^d UNIVERSITY OF ARKANSAS   (United States)

^e University Medical School   (Japan)

Author keywords

Bone mineral density; Chemotherapy induced alopecia; Cyclophosphamide; Parathyroid hormone; PTH CBD agonist; PTH CBD antagonist

Indexed keywords

CALCIUM; COLLAGEN TYPE 1; CYCLIC AMP; CYCLOPHOSPHAMIDE; HYBRID PROTEIN; PARATHYROID HORMONE COLLAGEN BINDING DOMAIN PROTEIN; PARATHYROID HORMONE[7-33] COLLAGEN BINDING DOMAIN PROTEIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ADVERSE OUTCOME; ALOPECIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DENSITY; CALCIUM BLOOD LEVEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; FEMALE; HAIR FOLLICLE; HAIR GROWTH; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; TISSUE DISTRIBUTION;

ALOPECIA; AMINO ACID SEQUENCE; ANIMALS; BONE DENSITY; COLLAGEN; CYCLOPHOSPHAMIDE; FEMALE; HORMONE ANTAGONISTS; IMMUNOSUPPRESSIVE AGENTS; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; PARATHYROID HORMONE; PEPTIDE FRAGMENTS; PROTEIN BINDING; RECEPTOR, PARATHYROID HORMONE, TYPE 1;

EID: 84863201729     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27379     Document Type: Article

References (40)

1. Lotfi-Jam K, Carey M, Jefford M, Schofield P, Charleson C, Aranda S. Nonpharmacologic strategies for managing common chemotherapy adverse effects: a systematic review. J Clin Oncol 2008;26:5618-29.
2. Cline BW. Prevention of chemotherapy-induced alopecia: a review of the literature. Cancer Nurs 1984;7:221-8.
3. Dorr VJ. A practitioner's guide to cancer-related alopecia. Semin Oncol 1998;25:562-70. (Pubitemid 28478062)
4. Botchkarev VA. Molecular mechanisms of chemotherapy-induced hair loss. J Investig Dermatol Symp Proc 2003;8:72-5. (Pubitemid 36900494)
5. Grevelman EG, Breed WP. Prevention of chemotherapy-induced hair loss by scalp cooling. Ann Oncol 2005;16:352-8. (Pubitemid 40458310)
6. Christodoulou C, Tsakalos G, Galani E, Skarlos DV. Scalp metastases and scalp cooling for chemotherapy-induced alopecia prevention. Ann Oncol 2006;17:350. (Pubitemid 43160130)
7. Jimenez JJ, Roberts SM, Mejia J, Mauro LM, Munson JW, Elgart GW, Connelly EA, Chen Q, Zou J, Goldenberg C, Voellmy R. Prevention of chemotherapy-induced alopecia in rodent models. Cell Stress Chaperones 2008;13:31-8.
8. Hesketh PJ, Batchelor D, Golant M, Lyman GH, Rhodes N, Yardley D. Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches. Support Care Cancer 2004;12:543-9. (Pubitemid 39062544)
9. Wang J, Lu Z, Au JL. Protection against chemotherapy-induced alopecia. Pharm Res 2006; 23:2505-14.
10. Schilli MB, Paus R, Menrad A. Reduction of intrafollicular apoptosis in chemotherapy-induced alopecia by topical calcitriol-analogs. J Invest Dermatol 1998;111:598-604. (Pubitemid 28452319)
11. Davis ST, Benson BG, Bramson HN, Chapman DE, Dickerson SH, Dold KM, Eberwein DJ, Edelstein M, Frye SV, Gampe RT, Jr, Griffin RJ, Harris PA, et al. Prevention of chemotherapy-induced alopecia in rats by CDK inhibitors. Science 2001;291:134-7. (Pubitemid 32056682)
12. Paus R, Handjiski B, Eichmuller S, Czarnetzki BM. Chemotherapy-induced alopecia in mice. Induction by cyclophosphamide, inhibition by cyclosporine A, and modulation by dexamethasone. Am J Pathol 1994;144: 719-34. (Pubitemid 24172061)
13. Danks JA, Ebeling PR, Hayman J, Chou ST, Moseley JM, Dunlop J, Kemp BE, Martin TJ. Parathyroid hormone-related protein: immunohistochemical localization in cancers and in normal skin. J Bone Miner Res 1989;4:273-8. (Pubitemid 19121804)
14. Lee K, Deeds JD, Segre GV. Expression of parathyroid hormone-related peptide and its receptor messenger ribonucleic acids during fetal development of rats. Endocrinology 1995;136: 453-63.
15. Shin JH, Ji C, Casinghino S, McCarthy TL, Centrella M. Parathyroid hormone-related protein enhances insulin-like growth factor-I expression by fetal rat dermal fibroblasts. J Biol Chem 1997;272:23498-502. (Pubitemid 27410916)
16. Orloff JJ, Wu TL, Stewart AF. Parathyroid hormone-like proteins: biochemical responses and receptor interactions. Endocr Rev 1989;10:476-95. (Pubitemid 20001020)
17. Holick MF, Ray S, Chen TC, Tian X, Persons KS. A parathyroid hormone antagonist stimulates epidermal proliferation and hair growth in mice. Proc Natl Acad Sci USA 1994;91:8014-6. (Pubitemid 24253876)
18. Peters EM, Foitzik K, Paus R, Ray S, HolickMF. A new strategy for modulating chemotherapy-induced alopecia, using PTH/PTHrP receptor agonist and antagonist. J Invest Dermatol 2001;117:173-8. (Pubitemid 34205698)
19. Safer JD, Ray S, Holick MF. A topical parathyroid hormone/parathyroid hormone-related peptide receptor antagonist stimulates hair growth in mice. Endocrinology 2007;148:1167-70.
20. Matsushita O, Jung CM, Minami J, Katayama S, Nishi N, Okabe A. A study of the collagen-binding domain of a 116-kDa Clostridium histolyticum collagenase. J Biol Chem 1998;273: 3643-8. (Pubitemid 28109790)
21. Chorev M. Parathyroid hormone 1 receptor: insights into structure and function. Receptors Channels 2002;8:219-42.
22. Gensure RC, Gardella TJ, Juppner H. Parathyroid hormone and parathyroid hormone-related peptide, and their receptors. Biochem Biophys Res Commun 2005;328:666-78. (Pubitemid 40208304)
23. Jonsson KB, John MR, Gensure RC, Gardella TJ, Juppner H. Tuberoinfundibular peptide 39 binds to the parathyroid hormone (PTH)/PTH-related peptide receptor, but functions as an antagonist. Endocrinology 2001;142:704-9. (Pubitemid 32222420)
24. Maretto S, Schievano E, Mammi S, Bisello A, Nakamoto C, Rosenblatt M, Chorev M, Peggion E. Conformational studies of a potent Leu11,D-Trp12- containing lactam-bridged parathyroid hormone-related protein-derived antagonist. J Pept Res 1998;52:241-8. (Pubitemid 28429533)
25. Bergwitz C, Jusseaume SA, Luck MD, Juppner H, Gardella TJ. Residues in the membrane-spanning and extracellular loop regions of the parathyroid hormone (PTH)-2 receptor determine signaling selectivity for PTH and PTH-related peptide. J Biol Chem 1997;272:28861-8. (Pubitemid 27498166)
26. Tamai E, Ishida T, Miyata S, Matsushita O, Suda H, Kobayashi S, Sonobe H, Okabe A. Accumulation of Clostridium perfringens epsilon-toxin in the mouse kidney and its possible biological significance. Infect Immun 2003;71: 5371-5. (Pubitemid 37070786)
27. Shimamoto S, Tamai E, Matsushita O, Minami J, Okabe A, Miyata S. Changes in ganglioside content affect the binding of Clostridium perfringens epsilon-toxin to detergent-resistant membranes of Madin-Darby canine kidney cells. Microbiol Immunol 2005;49:245-53.
28. Paus R, Schilli MB, Handjiski B, Menrad A, Henz BM, Plonka P. Topical calcitriol enhances normal hair regrowth but does not prevent chemotherapy-induced alopecia in mice. Cancer Res 1996;56:4438-43. (Pubitemid 26330452)
29. Tobin DJ, Hagen E, Botchkarev VA, Paus R. Do hair bulb melanocytes undergo apoptosis during hair follicle regression (catagen)? J Invest Dermatol 1998;111:941-7. (Pubitemid 29115158)
30. Muller-Rover S, Handjiski B, van der Veen C, Eichmuller S, Foitzik K, McKay IA, Stenn KS, Paus R. A comprehensive guide for the accurate classification of murine hair follicles in distinct hair cycle stages. J Invest Dermatol 2001;117: 3-15. (Pubitemid 32652434)
31. Katikaneni R, Ponnapakkam A, Miller E, Ponnapakkam T, Gensure RC. A new technique for precisely and accurately measuring lumbar spine bone mineral density in mice using clinical dual energy X-ray absorptiometry (DXA). Toxicol Mech Methods 2009;19:225-31.
32. Ponnapakkam T, Matsushita O, Sakon J, Gensure RC. Weekly administration of a novel parathyroid hormone-collagen binding domain fusion protein increases bone mineral density by more than 15% in normal mice. American Society for Bone and Mineral Research (ASBMR), 2025 M Street, NW, Suite 800, Washington DC 20036-3309, 2007.
33. Carter PH, Juppner H, Gardella TJ. Studies of the N-terminal region of a parathyroid hormone-related peptide (1-36) analog: receptor subtypeselective agonists, antagonists, and photochemical cross-linking agents. Endocrinology 1999;140: 4972-81.
34. Hirbe A, Morgan EA, Uluckan O, Weilbaecher K. Skeletal complications of breast cancer therapies. Clin Cancer Res 2006;12:6309s-14s.
35. Kim SH, Lim SK, Hahn JS. Effect of pamidronate on new vertebral fractures and bone mineral density in patients with malignant lymphoma receiving chemotherapy. Am J Med 2004; 116:524-8.
36. Barbehenn EK, Lurie P, Wolfe SM. Osteosarcoma risk in rats using PTH 1-34. Trends Endocrinol Metab 2001;12:383.
37. Rosenblatt M, Potts JT, Jr. Analogues of an invitro parathyroid hormone inhibitor: modifications at the amino terminus. Calcif Tissue Int 1981;33:153-7. (Pubitemid 11100007)
38. Carter PH, Petroni BD, Gensure RC, Schipani E, Potts JT, Jr., Gardella TJ. Selective and nonselective inverse agonists for constitutively active type-1 parathyroid hormone receptors: evidence for altered receptor conformations. Endocrinology 2001;142:1534-45. (Pubitemid 32299682)
39. Tosi A, Misciali C, Piraccini BM, Peluso AM, Bardazzi F. Drug-induced hair loss and hair growth. Incidence, management and avoidance. Drug Saf 1994;10:310-7. (Pubitemid 24126223)
40. Nakashima-Kamimura N, Nishimaki K, Mori T, Asoh S, Ohta S. Prevention of chemotherapy-induced alopecia by the anti-death FNK protein. Life Sci 2008;82:218-25.